Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population,Expert Review of Clinical Immunology

当前位置： X-MOL 学术 › Expert Rev. Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2024-01-21 , DOI: 10.1080/1744666x.2023.2284226
Valeria Dipasquale ₁ , Angela Alibrandi ₂ , Salvatore Pellegrino ₁ , Vincenzo Ramistella ₁ , Claudio Romano ₁

Affiliation

The pharmacokinetics and pharmacodynamics of biosimilar infliximab (IFX-BioS) in pediatric inflammatory bowel disease (IBD) are poorly investigated. The aim of this study was to investigate factors...

中文翻译：